These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 12713619)

  • 1. p53 Mutation and MDM2 amplification in inflammatory myofibroblastic tumours.
    Yamamoto H; Oda Y; Saito T; Sakamoto A; Miyajima K; Tamiya S; Tsuneyoshi M
    Histopathology; 2003 May; 42(5):431-9. PubMed ID: 12713619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular abnormalities of p53, MDM2, and H-ras in synovial sarcoma.
    Oda Y; Sakamoto A; Satio T; Kawauchi S; Iwamoto Y; Tsuneyoshi M
    Mod Pathol; 2000 Sep; 13(9):994-1004. PubMed ID: 11007040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of p53 and mdm2 proteins in malignant fibrous histiocytoma in absence of gene alteration: prognostic significance.
    Molina P; Pellín A; Navarro S; Boix J; Carda C; Llombart-Bosch A
    Virchows Arch; 1999 Dec; 435(6):596-605. PubMed ID: 10628802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparative study of P53/MDM2 genes alterations and P53/MDM2 proteins immunoreactivity in soft-tissue sarcomas.
    Rieske P; Bartkowiak JK; Szadowska AM; Olborski B; Harezga-Bal B; Debiec-Rychter M
    J Exp Clin Cancer Res; 1999 Sep; 18(3):403-16. PubMed ID: 10606188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p21WAF1/CIP1 and MDM2 expression in non-Hodgkin's lymphoma and their relationship to p53 status: a p53+, MDM2-, p21-immunophenotype associated with missense p53 mutations.
    Villuendas R; Pezzella F; Gatter K; Algara P; Sánchez-Beato M; Martínez P; Martínez JC; Muñoz K; García P; Sánchez L; Kocialkowsky S; Campo E; Orradre JL; Piris MA
    J Pathol; 1997 Jan; 181(1):51-61. PubMed ID: 9072003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inflammatory myofibroblastic tumor and low-grade myofibroblastic sarcoma: a comparative study of clinicopathologic features and further observations on the immunohistochemical profile of myofibroblasts.
    Qiu X; Montgomery E; Sun B
    Hum Pathol; 2008 Jun; 39(6):846-56. PubMed ID: 18400254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mdm2 gene amplification in gastric cancer correlation with expression of Mdm2 protein and p53 alterations.
    Günther T; Schneider-Stock R; Häckel C; Kasper HU; Pross M; Hackelsberger A; Lippert H; Roessner A
    Mod Pathol; 2000 Jun; 13(6):621-6. PubMed ID: 10874665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparative study of P53/MDM2 genes alterations and P53/MDM2 proteins immunoreactivity in liver cirrhosis and hepatocellular carcinoma.
    Jablkowski M; Bocian A; Bialkowska J; Bartkowiak J
    J Exp Clin Cancer Res; 2005 Mar; 24(1):117-25. PubMed ID: 15943041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MDM2 overexpression is associated with short survival in adults with medulloblastoma.
    Giordana MT; Duó D; Gasverde S; Trevisan E; Boghi A; Morra I; Pradotto L; Mauro A; Chió A
    Neuro Oncol; 2002 Apr; 4(2):115-22. PubMed ID: 11916503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heterogeneous distribution of P53 immunoreactivity in human lung adenocarcinoma correlates with MDM2 protein expression, rather than with P53 gene mutation.
    Koga T; Hashimoto S; Sugio K; Yoshino I; Nakagawa K; Yonemitsu Y; Sugimachi K; Sueishi K
    Int J Cancer; 2001 Jul; 95(4):232-9. PubMed ID: 11400116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular analysis for p53 and mdm2 in intracranial germ cell tumors.
    Iwato M; Tachibana O; Tohma Y; Nitta H; Hayashi Y; Yamashita J
    Acta Neuropathol; 2000 Jan; 99(1):21-5. PubMed ID: 10651023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalences of Gs alpha, ras, p53 mutations and ret/PTC rearrangement in differentiated thyroid tumours in a Korean population.
    Park KY; Koh JM; Kim YI; Park HJ; Gong G; Hong SJ; Ahn IM
    Clin Endocrinol (Oxf); 1998 Sep; 49(3):317-23. PubMed ID: 9861322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p53 gene mutations and expression of p53 and mdm2 proteins in invasive breast carcinoma. A comparative analysis with clinico-pathological factors.
    Günther T; Schneider-Stock R; Rys J; Niezabitowski A; Roessner A
    J Cancer Res Clin Oncol; 1997; 123(7):388-94. PubMed ID: 9260591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p53 mutation and MDM2 amplification are rare even in human papillomavirus-negative cervical carcinomas.
    Ikenberg H; Matthay K; Schmitt B; Bauknecht T; Kiechle-Schwarz M; Göppinger A; Pfleiderer A
    Cancer; 1995 Jul; 76(1):57-66. PubMed ID: 8630877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relative quantitation of p53 and MDM2 gene expression in leiomyosarcoma; real-time semi-quantitative reverse transcription-polymerase chain reaction.
    Miyajima K; Tamiya S; Oda Y; Adachi T; Konomoto T; Toyoshiba H; Masuda K; Tsuneyoshi M
    Cancer Lett; 2001 Mar; 164(2):177-88. PubMed ID: 11179833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Over expression of CDK4 and MDM2 in a patient with recurrent ALK-negative mediastinal inflammatory myofibroblastic tumor: A case report.
    Hou TC; Wu PS; Huang WY; Yang YT; Tan KT; Liu SH; Chen YJ; Chen SJ; Su YW
    Medicine (Baltimore); 2020 Mar; 99(12):e19577. PubMed ID: 32195970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FN1: a novel fusion partner of ALK in an inflammatory myofibroblastic tumor.
    Ouchi K; Miyachi M; Tsuma Y; Tsuchiya K; Iehara T; Konishi E; Yanagisawa A; Hosoi H
    Pediatr Blood Cancer; 2015 May; 62(5):909-11. PubMed ID: 25682942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methods.
    Lu ML; Wikman F; Orntoft TF; Charytonowicz E; Rabbani F; Zhang Z; Dalbagni G; Pohar KS; Yu G; Cordon-Cardo C
    Clin Cancer Res; 2002 Jan; 8(1):171-9. PubMed ID: 11801555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. P53 and MDM2 co-expression in tobacco and betel chewing-associated oral squamous cell carcinomas.
    Shwe M; Chiguchi G; Yamada S; Nakajima T; Maung KK; Takagi M; Amagasa T; Tsuchida N
    J Med Dent Sci; 2001 Dec; 48(4):113-9. PubMed ID: 12160248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. mdm-2 expression correlates with wild-type p53 status in esophageal adenocarcinoma.
    Soslow RA; Altorki NK; Yang G; Xie D; Yang CS
    Mod Pathol; 1999 Jun; 12(6):580-6. PubMed ID: 10392633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.